Physician profile
Andre G Gros
NPI 1215065073
$3,901.47
in general payments reported to CMS, 2019-2025
25 companies · $799 in 2025
The $799 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,000 · 2022: $615 · 2023: $842 · 2024: $645 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,071.77 |
| Education | $214.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $728.08 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $446.52 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $413.00 | 2021-2025 | Slynd |
| Astellas Pharma US INC | $373.08 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $346.02 | 2021-2023 | |
| Novo Nordisk INC | $307.41 | 2021-2025 | Wegovy, Saxenda |
| Amgen INC. | $254.71 | 2021-2025 | Evenity, Prolia, Prolia |
| Millicent US INC | $187.83 | 2021-2025 | Intrarosa, Femring, Femlyv |
| Bausch Health US, LLC | $145.96 | 2021-2023 | Wellbutrin, Aplenzin |
| Therapeuticsmd, INC. | $133.25 | 2021-2022 | |
| Myovant Sciences INC. | $106.90 | 2021-2022 | |
| Pfizer INC. | $95.01 | 2021-2025 | |
| Avion Pharmaceuticals | $76.08 | 2021-2023 | Balcoltra |
| Currax Pharmaceuticals LLC | $46.80 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $43.22 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $34.33 | 2021 | |
| Exact Sciences Corporation | $30.93 | 2025 | The Cologuard Plus Collection Kit |
| Alfasigma USA, INC. | $18.43 | 2022 | |
| Lilly USA, LLC | $17.99 | 2025 | Zepbound |
| Coloplast Corp | $17.72 | 2025 | |
| Merck Sharp & Dohme LLC | $17.12 | 2021 | |
| Sage Therapeutics, LLC | $16.36 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $16.28 | 2021 | |
| Evofem Biosciences, INC. | $16.07 | 2021 | |
| Coopersurgical, INC. | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Gros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.